Lung cancer is the most common cause of cancer-related death, worldwide. Historically,
lung cancer has been divided into two main histological types: small cell and nonsmall cell …

Lung cancer is the most common cause of cancer-related death worldwide, less than 7% of
patients survive 10 years following diagnosis across all stages of lung cancer. Late stage of …

Numerous variants of unknown significance (VUS) have been identified through large-scale
cancer genome projects, although their functional relevance remains uninvestigated. We …

Introduction Targeted somatic genomic analysis (EGFR, anaplastic lymphoma receptor
tyrosine kinase gene [ALK], and ROS1) and programmed death ligand 1 (PD-L1) tumor …

Introduction. Lung cancer is the most common malignant tumor and the main cause of tumor‐
related death globally. As the 5‐year survival rate of lung adenocarcinoma (LUAD) remains …

Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …

The identification of EGFR mutations and their respectively tyrosine kinase inhibitors (TKIs),
changed dramatically treatment and survival of patients with EGFR-positive lung cancer …

Introduction Among non-small cell lung cancer (NSCLC) patients, there is one molecularly
defined subgroup harboring activating mutations in the epidermal growth factor receptor …

Abstract Objectives For patients with Epidermal Growth Factor Receptor (EGFR)-mutated
non-small cell lung cancer (NSCLC), frontline EGFR-tyrosine kinase inhibitor (TKI) therapy …

Abstract Treatment with EGFR inhibitors is limited to patients with advanced/metastatic non-
small cell lung cancer who have known EGFR mutations. Currently, patient care has to …